Both in Pharmaceuticals
Lyell Immunopharma vs Opus Genetics
Over the past year LYEL returned −3.3% and IRD returned +96.8%; their daily moves had a correlation of 0.25.
LYEL −3.3% IRD +96.8%Growth of $1, one year, split-adjusted
| Metric | LYEL | IRD |
|---|---|---|
| Price | $15.43 | $4.27 |
| Market cap | $378.1M | $355.2M |
| Today | +43.27% | +8.65% |
| 1 month | +79.2% | −2.5% |
| 6 months | −26.0% | −18.8% |
| Year to date | −49.9% | +112.4% |
| 1 year | −6.8% | +99.5% |
| Revenue growth (YoY) | −50.0% | −73.8% |
| Gross margin | 100.0% | 100.0% |
| Net margin | −1118875.0% | −1072.6% |
| P/E (TTM) | — | — |
| Price / sales | 14,004.2× | 36.0× |
| Net cash | $204.1M | $53.9M |
| Dividend yield | — | — |
| Volatility (60d) | 101.1% | 93.5% |
| Short % of float | 15.8% | 21.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).